We are live on ! Find out more
NBIX icon

Neurocrine Biosciences
NBIX

218 hedge funds and large institutions have $4.7B invested in Neurocrine Biosciences in 2015 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 92 increasing their positions, 72 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

52% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 23

43% more capital invested

Capital invested by funds: $3.29B → $4.7B (+$1.41B)

29% more call options, than puts

Call options by funds: $36.2M | Put options by funds: $28.1M

28% more repeat investments, than reductions

Existing positions increased: 92 | Existing positions reduced: 72

5% more funds holding

Funds holding: 207 → 218 (+11)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

Holders
218
Holders Change
+11
Holders Change %
+5.31%
% of All Funds
5.72%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.1%
New
35
Increased
92
Reduced
72
Closed
23
Calls
$36.2M
Puts
$28.1M
Net Calls
+$8.07M
Net Calls Change
-$28.1M

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$43.9M
2
Citadel Advisors
Citadel Advisors
Florida
+$33.4M
3
SAM
Sectoral Asset Management
Quebec, Canada
+$21.2M
4
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$20.2M
5
JHIU
Janus Henderson Investors US
Colorado
+$19.9M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$66.1M
2
PA
Perceptive Advisors
New York
-$22.7M
3
Jennison Associates
Jennison Associates
New York
-$19.2M
4
TCP
Tourbillon Capital Partners
New York
-$18M
5
Millennium Management
Millennium Management
New York
-$13.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
CAM
126
ClariVest Asset Management
California
$1.87M +$437K +8,600 +35%
Two Sigma Advisers
127
Two Sigma Advisers
New York
$1.67M -$1.91M -37,500 -56%
SAM
128
Shell Asset Management
Netherlands
$1.56M +$1.4M +27,620 New
DCM
129
Dupont Capital Management
Delaware
$1.54M +$154K +3,030 +13%
NC
130
Nexthera Capital
New York
$1.53M +$1.37M +27,000 New
JMPWA
131
JP Morgan Private Wealth Advisors
California
$1.51M -$383K -7,530 -22%
Citigroup
132
Citigroup
New York
$1.5M +$429K +8,449 +47%
Neuberger Berman Group
133
Neuberger Berman Group
New York
$1.5M +$1.35M +26,487 New
LCG
134
Lisanti Capital Growth
New York
$1.44M -$335K -6,599 -21%
TAM
135
Tocqueville Asset Management
New York
$1.43M +$203K +4,000 +19%
TI
136
Trexquant Investment
Connecticut
$1.42M -$1.15M -22,686 -48%
MAM
137
Meeder Asset Management
Ohio
$1.39M +$1.25M +24,641 New
PPA
138
Parametric Portfolio Associates
Washington
$1.32M -$191K -3,751 -14%
BC
139
Birchview Capital
Vermont
$1.31M +$686K +13,500 +139%
Public Employees Retirement Association of Colorado
140
Public Employees Retirement Association of Colorado
Colorado
$1.22M – – –
PAM
141
Paradigm Asset Management
New York
$1.19M -$2.3M -45,200 -68%
WC
142
Woodstock Corp
Massachusetts
$1.13M – – –
TI
143
Turner Investments
Pennsylvania
$1.02M -$1.02M -20,000 -53%
SGAM
144
Smith Group Asset Management
Texas
$1.01M +$908K +17,870 New
SO
145
STRS Ohio
Ohio
$984K +$158K +3,100 +22%
Legal & General Group
146
Legal & General Group
United Kingdom
$980K +$48.7K +958 +6%
BNP Paribas Financial Markets
147
BNP Paribas Financial Markets
France
$963K -$21.8K -429 -2%
WMSA
148
Weiss Multi-Strategy Advisers
New York
$962K – – –
WSA
149
Wall Street Associates
California
$957K -$20.3K -400 -2%
CC
150
Callan Capital
California
$849K – – –
4 5
6
7 8

NBIX Hedge Fund Activity: Q4 2015 in Review

218 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q4 2015, worth a combined $4.7B — up 43% from $3.29B a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new NBIX positions and 23 closed out — a net gain of 12 holders — while 92 added to existing stakes and 72 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $43.9M. The largest seller was OrbiMed, cutting an estimated $66.1M.

  • 218 institutional investors held Neurocrine Biosciences (NBIX) as of Q4 2015, up from 207 in Q3 2015.
  • Funds reported $4.7B of Neurocrine Biosciences stock for Q4 2015, up 43% quarter-over-quarter.
  • 35 funds opened new Neurocrine Biosciences positions in Q4 2015 and 23 closed out, a net change of +12 holders.
  • The largest Neurocrine Biosciences buyer in Q4 2015 was T. Rowe Price Associates, an estimated $43.9M added.
  • The largest Neurocrine Biosciences seller in Q4 2015 was OrbiMed, an estimated $66.1M sold.

Based on aggregated 13F filings for Q4 2015.